论文部分内容阅读
目的:观察吉西他滨联合奥沙利铂(L-OHP)、左旋门冬酰胺酶(L-ASP)对复发性或难治性进展型非霍奇金淋巴瘤的疗效和不良反应。方法:吉西他滨1000mg/m2,d1,d8,静脉滴注;L-OHP 80mg/m2,d1,d8,静脉滴注;L-ASP 1000 u/d,d1-d8静脉滴注。3-4周为一个化疗周期。20例复发性或难治性进展型非霍奇金淋巴瘤患者,疗程不少于3个周期。结果:20例患者中,14例获得缓解,占77.8%。其中完全缓解(CR)6例,部分缓解(PR)8例。6例具有B类症状的患者中,4例症状消失,1例明显改善,1例无改善。化疗不良作用主要为轻度的胃肠道反应,极少数患者出现严重的骨髓抑制。结论:吉西他滨联合L-OHP、L-ASP对复发性或难治性进展型非霍奇金淋巴瘤有较好的近期疗效,能明显改善患者症状,且大部分患者可以承受其不良反应,是一个值得进一步验证的补救性化疗方案。
Objective: To observe the efficacy and side effects of gemcitabine plus oxaliplatin (L-OHP) and L-asparaginase (L-ASP) on patients with recurrent or refractory advanced non-Hodgkin’s lymphoma. Methods: Gemcitabine 1000mg / m2, d1, d8, intravenous drip; L-OHP 80mg / m2, d1, d8, intravenous drip; L-ASP 1000 u / d, d1-d8 intravenous drip. 3-4 weeks for a chemotherapy cycle. 20 patients with recurrent or refractory advanced non-Hodgkin’s lymphoma, treatment of not less than 3 cycles. Results: Of the 20 patients, 14 were relieved, accounting for 77.8%. Among them, 6 were complete remission (CR) and 8 were partial remission (PR). Of the 6 patients with type B symptoms, 4 had no symptoms, 1 had a significant improvement and 1 had no improvement. The adverse effects of chemotherapy are mainly mild gastrointestinal reactions, very few patients with severe myelosuppression. CONCLUSION: Gemcitabine combined with L-OHP and L-ASP has a good short-term curative effect on recurrent or refractory advanced non-Hodgkin’s lymphoma. It can significantly improve the symptoms of patients and most patients can tolerate the adverse reactions. A salvage chemotherapy regimen worth further validation.